Mark C. Johnson, CFA, MBA
Board of Directors
Senior Director, Investor Relations, ACADIA Pharmaceuticals Inc.
Mark Johnson currently serves as senior director, Investor Relations for ACADIA Pharmaceuticals Inc., a publicly traded biopharmaceutical company in San Diego focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.
In Johnson’s role he is charged with communicating the ACADIA story to Wall Street investors, analysts and bankers. In addition, he works directly with executive management and the board of directors on strategic and corporate finance initiatives.
Previously, Johnson worked as senior director of Investor Relations for aTyr Pharma, a publicly traded biopharmaceutical company focused on immune-mediated diseases, including a clinical-stage program for the treatment of interstitial lung disease. Prior to aTyr, Johnson served as director of Investor Relations for SoftBank Group, a $100 billion market cap technology conglomerate headquartered in Tokyo, Japan. There he led all U.S.-based investor relations activities out of the San Francisco area. Before that he worked at DeNA, a successful Japanese internet company also based in Tokyo.
Johnson started his career in San Diego at another biopharmaceutical company, MediciNova, which is developing new treatments for patients with multiple sclerosis, idiopathic pulmonary fibrosis and acute exacerbations from asthma and COPD.
Johnson earned his M.B.A. from UCSD’s Rady School of Management and his B.A. in Economics from Cornell University. Johnson is also a CFA® charterholder.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.